# MK0431 (Sitagliptin) Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus (0431-055)(COMPLETED)

> **NCT00372060** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 134 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** sitagliptin phosphate
- **DRUG:** Comparator: sitagliptin phosphate (MK0431)
- **DRUG:** Comparator: pioglitazone
- **DRUG:** Comparator: placebo (unspecified)

## Key facts

- **NCT ID:** NCT00372060
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08-21
- **Primary completion:** 2008-02-05
- **Final completion:** 2008-02-05
- **Target enrollment:** 134 (ACTUAL)
- **Last updated:** 2017-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00372060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00372060, "MK0431 (Sitagliptin) Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus (0431-055)(COMPLETED)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00372060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*